In patients treated in the first line with pembrolizumab monotherapy, the presence of a KRAS G12C mutation associated with a TP53 co-mutation is associated with a major clinical benefit (ORR 100.0%, PFS 33.3 months, OS NA) [15], mediated by highly active interferon gamma signaling in a proinflammatory tumor microenvironment [26]. Here, KRAS is linked to neoplasm.